ghk-cu and reta GHK-Cu Dosage and Protocol: The

A common knee-focused stack: BPC-157: 250 mcg twice daily, injected subcutaneously near the knee TB-500: 2-2.5 mg twice per week, injected subcutaneously (abdomen or near knee) TB-500 works systemically due to its larger molecular size and longer half-life

Exosome treatments have not been approved by the FDA for any therapeutic use in humans

Glow Blendis a compound peptide research formulation combiningBPC-157,TB-500 (Thymosin Beta-4 fragment), andGHK-Cu, three peptides frequently examined in laboratory settings for their roles in cellular signaling, tissue modeling, inflammatory modulation, and extracellular matrix dynamics

References: He L, Feng D, Guo H, Zhou Y, Li Z, Zhang K, Zhang W, Wang S, Wang Z, Hao Q, Zhang C, Gao Y, Gu J, Zhang Y, Li W, Li M

May support collagen production, skin elasticity, wound healing, and hair growth